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Marine environment has been the source of diverse life forms that produce diﬀerent biologically active compounds. Marine
organisms are consistently contributing with unparalleled bioactive compounds that have profound applications in nutraceuticals,
cosmeceuticals, and pharmaceuticals. In this process, screening of natural products from marine organisms that could potentially
inhibit the expression of metalloproteinases has gained a huge popularity, which became a hot ﬁeld of research in life sciences.
Metalloproteinases, especially, matrix metalloproteinases (MMPs) are a class of structurally similar enzymes that contribute to the
extracellular matrix degradation and play major role in normal and pathological tissue remodeling. Imbalance in the expression
of MMPs leads to severe pathological condition that could initiate cardiac, cartilage, and cancer-related diseases. Three decades of
endeavor for designing potent matrix metalloproteinase inhibitory substances (MMPIs) with many not making upto ﬁnal clinical
trials seek new resources for devising MMPIs. Umpteen number of medicinally valuable compounds being reported from marine
organisms, which encourage current researchers to screen potent MMPIs from marine organisms. In this paper, we have made an
attempt to report the metalloproteinase inhibiting substances from various marine organisms.
1.Introduction
Metalloproteinases are a family of proteolytic enzymes
generally termed as endopeptidases. This group of endopep-
tidases majorly consists of enzymes from metzincin family
that include serralysins, astacins, adamalysins (a disintegrin
and metalloproteinase domain or ADAMs), and matrixins
(matrix metalloproteinases or MMPs) [1, 2]. The involve-
ment of the regulated degradation of extracellular matrix
(ECM) is essential for the physiological remodeling pro-
cesses like tissue repair, development, and morphogenesis.
Interestingly, the remodeling process found to be uncon-
trolled and deleterious immunological response to repair
the tissue damages, which was credited by cardio-related
ailments, cancer, and arthritis [3]. MMPs are exception-
ally studied and focused because of their evident role in
carcinogenesis and cellular invasion by catabolising the
ECM [2]. MMPs are zinc-dependant endopeptidases that
degrade the ECM [4] and this remodeling of ECM facilitates
several physiological processes like wound healing, bone
resorption, uterine involution, and organogenesis as well
as pathologic conditions including inﬂammatory, vascular,
and autoimmune disorders, and carcinogenesis [5]. Until
n o w ,a b o u t2 5 M M P Sh a v eb e e nr e p o r t e di nw h i c h2 4a r e
found in mammals [6]. It was assumed that the MMPs
and their role was conﬁned to the degradation of ECM.
However, recent scientiﬁc ﬁndings from several groups have
established that MMPs cleave a wide range of extracellular,
bioactive substrates, and regulating the activity of such
proteins, typically in a gain-of-function manner, may indeed
be the predominant function of MMPs in vivo, [6, 7]. In
addition to that, MMPs play a predominant role in tumor
invasion, angiogenesis, metastasis, transformation of cancer
cells, signal transduction, and apoptosis [8].
Structurally, MMPs share a common domain structure,
which includes propeptide domain, a catalytic metallopro-
teinase domain, a linker peptide often referred as hinge
region and a hemopexin domain [9]. The catalytic zones2 Biochemistry Research International
of MMPs are compact, spherical and approximately 165
amino acid residues long with a substrate binding cleft.
The extended zinc-binding motif harbors 3 zinc-binding
histidines and a glutamate that preferentially serves as
acid/base during catalytic reactions. MMP molecules possess
three α-helices and a ﬁve-stranded β sheet as well as at
least two calcium sites and a second zinc site which renders
structural functions for these molecules [10]. The substrate
speciﬁcity of MMPs is determined by a hydrophobic pocket
called S1
 pocket which is found at the catalytic domain.
HencetheS1
 pocketthatdeterminesthesubstratespeciﬁcity
for MMPs becomes an inevitable source to devise MMP
inhibitors [10].
Generally, intercellular regulation and cell matrix adhe-
sion is regulated in a controlled manner, however, pre-
dominant human-related cancers are found with the dys-
regulation of these two phenomena. These pathological
changes are due to the superior expressions of MMPs,
the proteolytic enzymes [11]. The regulation of MMPs is
controlled by endogenous inhibitors like tissue inhibitors
of metalloproteinase (TIMPs), α2-macroglobin, heparin,
and the reversion-inducing cysteine-rich protein with kazal
motifs. TIMPs are naturally occurring inhibitors of MMPs
and they form noncovalent 1:1 stoichiometric complexes
with MMPs and prevent the proteolytic degradation [12].
Although the TIMPs have inhibitory activities on MMPs,
they diﬀer in many aspects like solubility, interaction with
proenzymes (Pro-MMPs) and also regulation of expression
[13]. Interactions and regulation of speciﬁc MMPs and other
proteasesbyspeciﬁcmembersofTIMPfamilyarethoroughly
discussed elsewhere [14–17].
MMPs association with various pathological responses
has initiated an outstanding scientiﬁc preference to design
the most potent MMPIs in the last 20 years. Many potential
MMPIs have been formulated, however the challenging
concept was that these inhibitors displayed poor selectivity
towards MMP members and also the signiﬁcance of blocking
unrelated zinc proteases became an obstacle [18]. The
strategies of designing MMPIs were based on the chelating
of Zn2+ that induces inhibition of MMPs. Chelating groups
like hydroxyl amine, carboxyl, thiol and so forth, were
predominantly used. Commercially successful MMPIs like
Batimastat (BB-94), Marimastat (BB-516) are known to
have strong Zn2+ chelating group, hydroxamate. The poor
selectivity, improper metabolism, low oral bioavailability,
poor solubility, side eﬀects like musculoskeletal pain and
inﬂammation, complications and the risk of increased drug
toxicity have strongly eliminated the ﬁrst generation MMPIs
from clinical trials [9, 19, 20].
As the above discussed scientiﬁc observations clearly
bring front the point of reported MMPIs’ failure in clinical
trials, the need of designing novel MMPIs speciﬁc to MMPs
is being the major concern. The new generation MMPI
research suggests that the thorough study on S1
 pocket of
MMPs could increase the selectivity of MMPs and also is
thought to prove beneﬁcial in reducing the risk of other
MMP-related diseases [21, 22]. According to Chen et al.,
the MMPIs can be broadly divided into 4 classes: the
naturalMMPIssecretedbytissues;syntheticMMPIs;MMPIs
screened from natural products; the MMPIs screened from
the phage display random peptide library and antibody
library. However, as the synthetic MMPIs indeed have
few shortcomings at clinical usage, MMPIs derived from
natural sources are being considered more for current time
research. Until now, umpteen number of research groups
have worked to achieve MMPIs from terrestrial sources and
reported several outstanding natural MMPIs [23, 24]. For
ages, it has been believed and proved that oceans harbor
a variety of life forms ranging from microorganisms to
vertebrates, which in turn provide mankind with several
beneﬁts biologically and medicinally. This feature of wide
diversity in marine life forms has been identiﬁed as chief
source for unique biologically active compounds that exhibit
tremendous potential for pharmaceutical applications [25].
As these oceanic organisms are not completely exploited or
studied well for their medicinal values, this ﬁeld of research
has gained lots of attention these days. This paper narrates
a descriptive past research work carried out on MMPIs
derived from marine organisms and in addition, the speciﬁc
areas of metalloproteinase research have been outlined in a
perspective manner.
2.MarineAnimals
Fish from marine sources are abundant in omega-3 long-
chain polyunsaturated fatty acids (ω3 LC-PUFAs) like eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Jud´ e et al. have reported and compared some proposed
mechanisms for the involvement of omega-3 LC-PUFAs
in both cardiac and breast cancer protection [26]. Simple
products like dietary oils from ﬁsh have been reported to
exert beneﬁcial properties in lowering the expressions of
proMMP-2 and proMMP-9, that makes the dietary ﬁsh oil, a
potential MMP inhibiting substance and can reduce the risk
of inﬂammatory joint diseases [27]. Another research group
has reported that oleic acid (OA), docosahexaenoic acid
(DHA), and eicosapentaenoic acid (EPA) have signiﬁcantly
inhibited the lung metastasis by colon-carcinoma-26 cells
by downregulating the activities of MMP-2 and -9 [28].
Diets supplemented with DHA reduce the metalloproteinase
production in uterus, placenta, and liver tissues of rat. These
ﬁndings suggest that competitive incorporation of ω3L C -
PUFAs and arachidonic acid into membrane phospholipids
would consequently aﬀect the MMP activities by bringing
a change in the production of prostaglandin PGE2 [29]. A
21-kDa proteinase inhibitor from Gadus morhua (Atlantic
cod) that shares similar properties to that of human TIMP-
2 was investigated by Lødemel et al., whose studies revealed
that this inhibitor has suppressed the gelatinolytic activity
obtained from a human macrophage cell medium rich in
MMP-9 [30], recommending it as a potent MMP inhibiting
marine substance. Similar to this, shark cartilage is a
source of antiangiogenic and antitumor compounds [31].
A novel antiangiogenic and antiinﬂammatory agent, AE -
941 from shark cartilage has been studied by Dupont et
al., who reported the eﬀectiveness of this substance in
treating psoriasis [32]. Compounds extracted from shark
cartilage such as Neovastat , AE-941, U-995 have beenBiochemistry Research International 3
checked for their antiangiogenic and antimetastatic eﬀects.
Neovastat has been found to inhibit MMP-2 and partially
MMP-1, -7, -9 and -13. Western blot analysis conﬁrms the
presence of TIMP-like proteins within AE-941 that might
be responsible in inhibiting the MMPs [33]. Our previous
studies of potent ACE inhibitory peptide from tuna frame
protein (PTFP) hydrolysate has shown antihypertensive
eﬀectinspontaneouslyhypertensiverats(SHRs)[34].Earlier
scientiﬁc investigations proved that ACE and MMPs are
closely related to coronary diseases and the ACE inhibitors
not only target ACE but also MMPs. Yamamoto and Takai
have postulated that molecular interaction between MMP-9
activesitesandACEinhibitorscouldbrightenupthechances
for MMP inhibitors for cardioprotection [35].
Marine cephalopods and their metabolites have been
reported to have many applications in the ﬁeld of medicine.
SIP-SII is the sulfated ink polysaccharide (SIP) isolated
from cuttleﬁsh; Sepiella maindroni has been evaluated for
its ability to inhibit the invasion and migration of SKOV3
and ECV304 cells via inhibition of MMP-2 proteolytic
activity [36]. The backbone of SIP-SII is composed of fucose,
N-acetylgalactosamine, mannose, and a single branch of
glucuronic acid at the C-3 position of mannose with 34.7%
of sulfated group [46]. Sulphated polysaccharides are known
fortheirinhibitionpotentialofMMPs[47–50]andespecially
the metastasis in cancer is strongly inhibited by the O-
Sulfated polysaccharide [51]. Thus SIP-SII can be considered
as a substance that can inhibit MMP-2 expression. According
to Chen et al., SIP-named TBA-1 from the ink of Ommas-
trephes bartrami potentially inhibits the cell invasion and
migration in HepG2, which proved once again that SIPs are
becomingthebestcandidatesasmetalloproteinaseinhibiting
substances [52].
Marine sponges by being the most diversiﬁed fau-
nal communities of seas, have contributed in discovering
potential MMP inhibiting compounds. Ageladine A (1),
a ﬂuorescent alkaloid isolated from marine sponge Agelas
nakamurai has the capability of inhibiting not only MMP-
2 but also MMP-1, -8, -9, -12, and -13. This compound also
inhibited the migration of bovine aortic endothelial (BAE)
cells signiﬁcantly. However, the mechanism of inhibiting
the MMPs is not clear because the research results say that
Ageladine A (1) did not chelate the Zn+2 and moreover
the mode of inhibition is presumed to be other than the
competitiveinhibition[37].AnotherstudyonAncorinosides
B, C, D isolated from the marine sponge Penares sollasi
Thiele has shown an inhibitory eﬀect on membrane type 1
matrix metalloproteinase (MT1-MMP) with IC50 values of
180–500μg/mL. These ancorinosides contain two carboxylic
acids and a tetramic acid group and it is presumed that
the latter plays an eﬀective role in the inhibition of MMPs
[38] .A na n t i b a c t e r i a lb r o m i n a t e dc o m p o u n dp r o d u c e db y
certain sponges named (+)-aeroplysinin-1 exhibited a clear
inhibitory eﬀect on the migration capabilities of endothelial
cells. The inhibitory eﬀects on MMP-2 and urokinase are
revealedbythezymographicstudiessuggestingaeroplysinin-
1 as a promising drug for angiogenesis-related pathologies
[53]. According to the review by R. G. Kerr and S. S. Kerr
debromohymenialdisine and its related compounds from a
sponge genus Hymeniacidon were reported to inhibit the calf
joint cartilage degradation by downregulating the metallo-
proteinases [54]. Poecillastra sp. and Jaspis sp. are known
to harbor Psammaplin A (PsA) a natural bromotyrosine
[55], where PsA is reported to have strong antiproliferative,
antiangiogenicproperties,whichundoubtedlysuggestPsAas
a potential antiangiogenic agents [56].
Recently, a novel oligopeptide SHP-1, rich in acidic
amino acids, aspartic acid (Asp) and glutamic acid (Glu)
was isolated from sea horse Hippocampus Syngnathidae [39].
The sequence of the isolated oligopeptide is LEDPFDKD-
DWDNWKS, which was investigated for its ability to inhibit
the expression of MMP-1, -3 and -13 thus preventing the
cartilage damage in human chondrocytic (SW-1353) and
osteoblastic (MG-63) cells. These results strongly support
that metalloproteinases possess binding sites that are open
for Asp and Glu and also Asp helps in rejuvenation of
cell formation, cellular activity, and metabolism [57]. The
cartilage preventive property of SPH-1 could be possible
because of its down regulatory eﬀect on the expression of
MMP-1 and -13 which are thought to play a key role in the
destruction of cartilage [58] . The same research group has
reported pronase E-derived hydrolysate peptide of 1821 Da
from a sea horse, Hippocampus kuda Bleeler. This peptide
has been checked for its induction of diﬀerentiation of
osteoblasticMG-63andchondrocyticSW-1353cellsbymea-
suring ALP activity, mineralization, and collagen synthesis.
Interestingly, their results indicate that the respective peptide
has considerably inhibited the MMP-1, -3 and -13 by picking
the mechanism of reducing p38 kinase/NF-κBi nM G - 6 3
cells and MAPKs/NF-κB in SW-1353 cells [59]. These results
clearlyindicatethatmarineorganismsareanexcellentchoice
to devise MMPIs. Analysis of a gene for naturally occurring
TIMP from paciﬁc oyster Crassostrea gigas named cg-TIMP,
the ﬁrst tissue inhibitor of metalloproteinase from mollusks,
revealed that it is closely related to vertebrate TIMP family
and is eﬀectively involved in wound healing as well as in
defense mechanisms [60]. Exploitation of this feature by
the use of gene technology could result in potential natural
MMPI mimics that could be compatible for humans.
Mucopolysaccharide called chitin from crustacean shells
has been known for its vast application in nutraceuti-
cals and as well as pharmaceuticals. Kong et al. syn-
thesized water-soluble derivatives of chitin and chitosan,
carboxymethyl-chitosan (CM-chitosan) and carboxymethyl-
chitin(CM-chitin)bymeansofcarboxymethylationreaction
and evaluated their eﬀect on the expressions of MMPs.
As per their investigations, CM-chitin exhibited a higher
MMP inhibitory, (MMP-2 and MMP-9) eﬀect than CM-
chitosan through transcriptional downregulations of activa-
tor protein-1 (AP-1) and nuclear factor κB( N F - κB), thus
reporting CM-chitin and CM-chitosan as strong antioxi-
dants and potent MMP inhibiting natural polymers [61].
Chitooligosaccharides (COS) ranging from 3–5kDa has
been reported to have a strong inhibitory eﬀect on MMP-
2 by decreasing the gene expression and transcriptional
activity of MMP-2. Moreover COS of the same molecular
weight represses the gene expression of c-fos, a part of
AP-1 transcription factor suggesting that they can combat4 Biochemistry Research International
Table 1: List of important substances from marine organisms that inhibit metalloproteinases.
Substance Structure References
Sulfated ink
polysaccharide
(SIP)
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Table 1: Continued.
Substance Structure References
Isorhamnetin 3-
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metalloproteinase-related pathological processes like metas-
tasis and wrinkle formation [62]. Rajapakse et al. have
reported that carboxylated chitooligosaccharides (CCOS)
downregulatetheMMP-9expressioninhumanﬁbrosarcoma
(HT-1080) cells. In addition, CCOS is able to reduce the
expression of MMP-9 by downregulating the MMP-9 at
transcription level, mediated via the inhibition of AP-1 [63].
Brito et al. have reported about antiinﬂammatory prop-
erties of a heparin-like compound from the shrimp Litope-
naeus vannamei. Their observations postulated that this
compound has not only reduced the inﬂux of inﬂammatory
cells to injury site but also has an outstanding capability of
inhibiting MMP-9 activity to 90%. The structural feature
of this heparin-like protein from shrimp which has high6 Biochemistry Research International
content of glucuronic acid and disulfated disaccharide units
renders the anticoagulant and hemorrhagic activities, which
clearly recommends this heparin like substance as better
antiinﬂammatory drug [64]. Heparinoid from shrimp has
been reported to have potent antiangiogenic and antiin-
ﬂammatory activities with insigniﬁcant anticoagulant or
hemorrhagic actions, thus making shrimp heparinoid as
a potent drug to treat neovascular age-related macular
degeneration (AMD) and other angioproliferative diseases
[65].
3.MarinePlants
Metabolites from marine plants have been reported to
have outstanding biological activities. A highly eﬀective
anticoagulant and antiproliferative agent called, sulfated
polysaccharidehasbeenreported fromabrownalga Ecklonia
cava, which exhibited a promising antiproliferative eﬀect
on human promyelocytic leukemia (HL-60) and human
leukemic monocyte lymphoma (U-937) cells at an IC50
value of 43.9μg/mL [66]. Fucoidan extracts from seaweed
Cladosiphon novae-caledoniae Kylin (Mozuku) have reduced
the cellular invasiveness in human ﬁbrosarcoma HT1080
cells by suppressing the activity of MMP-2 and MMP-9.
Further, it has been reported that these fucoidan extracts
suppressed the expression and secretion of an angiogenesis
factor, vascular endothelial growth factor (VEGF) thereby
reporting the inhibitory eﬀects on invasion and angiogenesis
of tumor cells [67]. Fucoidan from Costaria costata of the
order Laminariales, has an outstanding inhibitory eﬀect of
minimizing UV-B-induced MMP-1 expression by 41.8% at
0.01μg/mL, 57.7% at 0.1μg/mL, and 70% at 1μg/mL, com-
pared to UVB irradiation alone (P<. 05) in immortalized
human keratinocyte (HaCaT) cells [40].
Methanolic extracts from marine red alga Corallina
pilulifera (CPM) have potentially reduced the expression of
UV-induced MMP-2 and MMP-9 in human dermal ﬁbrob-
last (HDF) cell suggesting CPM as an eﬀective antiphoto
ageing agent [68]. In spirit of designing new antiphotoaging
agents, Joe et al. reported that extracts from 3 species of Alar-
iaceae,Eiseniabicyclis,Eckloniacava,andEckloniastolonifera,
have strongly reduced MMP-1 expression via inhibiting both
NF-kappaB and AP-1 reporter. Moreover attenuation of
MMP-1 expression was evident by treatment with eckol or
dieckol, which were purely isolated from E. stolonifera in
human dermal ﬁbroblasts [41]. The phlorotannins eckol
and dieckol were ﬁrst isolated from Ecklonia species possess
oligomeric polyphenol of phloroglucinol unit [69]. Various
biological activities including free radical scavenging activity
of phlorotannins from Ecklonia species have been reported
earlier [70]. Dieckol from marine brown alga, E. cava has
been reported to suppress LPS-induced production of nitric
oxide (NO) and prostaglandin E2 (PGE2) and expression of
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2
(COX-2) in murine BV2 microglia, thus establishing dieckol
as a potent antiinﬂammatory and neuroprotective agent
[71].
Salicornia herbacea, a halophyte that grows on salt
marshes and muddy seashores along the western coast of
Korea. Kong et al. have reported that ﬂavonoid glyco-
sides, isorhamnetin 3-O-β-d-glucoside, and quercetin 3-O-
β-d-glucoside isolated from this plant have inhibited the
expression of MMP-2 and MMP-9 and elevated the TIMP-
1 expression in human ﬁbrosarcoma (HT1080) cells, which
was conﬁrmed by western blot. The biological activity
of these ﬂavonoids is believed to be contributed by the
presence of phenolic hydroxyl groups [72]. Moreover, the
downregulation of MMP-9 and MMP-2 by these ﬂavonoids
is due to the interference with the transcription factor AP-
1 there by suggesting these ﬂavonoid glycosides as potent
natural chemopreventive agents for cancer [42]. Mook-Jung
et al. have worked on the constituents of two Rhodiola plants,
Rhodiola sacra S. H. Fu and Rhodiola sachalinensis A. Bor,
reporting that out of the 58 compounds tested, six had
considerable protective eﬀects against beta-amyloid-induced
death of B103 neuronal cells in vitro [73]. The extracts from
seagrassZost er amarinaL.,apigenin-7-O-β-D-glucoside (1),
chrysoeriol (2),andluteolin (3)canscavengereactiveoxygen
species.Especially,luteolinhasremarkableinhibitoryactivity
on MMP-1 for upto 44% at 4.0uM. The research results
suggest that luteolin (3) inhibited the MMP-1 expression by
suppressing the IL-6 expression by 30% at 4.0μM[ 43]. It
suggests that these extracts can combat photoaging induced
by UV rays.
In the exploration of marine natural antioxidants,
two bioactive isolates ﬂoridoside and d-isoﬂoridoside from
marine edible red alga Laurencia undulata have been studied
by Li et al. and are reported for their profound eﬀect
on scavenging free radicals and inhibiting the metallopro-
teinases MMP-2 and -9. The structure-activity relationships
(SARs) studies suggest that the eﬀective antioxidant activity
of these ﬂoridosides is rendered by the galactose group
and glycerol residue which can donate hydrogen ion and
in turn excited hydroxyl groups can attract electrons easily
[74]. Phlorotannins from brown alga E. cava have been
reported to have inhibitory activity on MMP-2 and MMP-
9 signifying the role of phlorotannins as potential and safe
marine derived MMPIs [75]. These ﬁndings clearly suggest
that puriﬁed extracts from E. cava inhibit MMP activity at a
lower concentration and reduce the incidence of metastasis
and skin wrinkle in vivo model.
4.MarineMicroorganisms
Around 70%–80% of marine environment is dominated
by various kinds of microorganisms that possess biologi-
cally active compounds. Calcium spirulan (Ca-SP) isolated
from Spirulina platensis, a marine unicellular alga was
able to reduce the melanoma (as studied in B16-BL6
cells), carcinoma (evidenced in colon 26-M3.1 cells), and
ﬁbrosarcoma (evidenced in HT-1080 cells). These ﬁndings
conﬁrm the possible role of Ca-Sp in interfering with the
MMPs and disabling the tumor invasion [76]. Yang et
al. reported that polysaccharide extract from S. platensis
(PSP) inhibits corneal neovascularization (CNV) caused by
alkali burns. Their ﬁndings clearly show that application of
PSP has reduced several parameters related to CNV and/orBiochemistry Research International 7
inﬂammation including the downregulation of MMP-2 and
MMP-9 [77]. Species of Chlorella are known for their
vast application in nutraceuticals. However, antioxidants
extracted from Chlorella vulgaris by a special supercritical
carbon dioxide extraction (SC-CO2)t e c h n o l o g yh a sp r o v e n
advantage in inhibiting MMP-mediated cancer proliferation
and progression via the suppression of cellular invasion and
metastasis [78].
Asolkar et al. reported arenamides A-C (1–3), from
Salinispora arenicola, a marine bacterial strain and the
eﬀect of arenamides A and B on NFκB activity in stably
transfectedto293/NFκB-Luchumanembryonickidneycells,
which revealed an outstanding blockage of TNF-induced
activation. As expression of MMP-9 gene is an outcome
of NFκB activity, further sophisticated studies could make
the arenamides potential MMP inhibiting compounds [44].
Marine bacterium Salinispora tropica renders salinospo-
ramide A (also called NPI-0052), which was recently identi-
ﬁed by Ahn et al. They have monitored the salinosporamide
A’s ability to potentiate the apoptosis induced by tumor
necrosis factor-α (TNF-α), bortezomib, and thalidomide,
and this mechanism was correlated with the downregulation
of cancer-related gene products including MMP-9 that plays
a role in tumor invasion. Thus by suppressing the NF-κB
pathway salinosporamide proved to be a promising MMP
inhibiting molecule [45].
5. Conclusions
In recent years, oceans’ ﬂora and fauna have been studied
extensivelyfortheirbiochemicalresponsestoevadepotential
threats they encounter in marine locales. This has led
to the idea of exploiting those biochemicals, in other
words natural products to be used as potential inputs in
medicinal applications that would prove to be beneﬁcial in
uplifting human health. The recent scientiﬁc investigations
unleashing the prominence of metalloproteinases in several
human-related ailments and the drawbacks of the currently
available synthetic antimetalloproteinases encourages the
present day researchers to explore natural resources for
moredevisingreliableandspeciﬁcMMPIs.SyntheticMMPIs
have few shortcomings like nonspeciﬁc selectivity, improper
metabolization that often leads to undesirable side eﬀects,
poor bioavailability and so forth. These have been the
key reasons to put most of the synthetic MMPIs out of
clinical trials. While on the other side, MMPIs from marine
organisms like ﬁsh, mollusks, cephalopods, red algae, brown
algae, few marine bacteria have reportedly given much
promising results (Table 1). However, screening of MMPIs
from marine organisms that speciﬁcally bind to the S1

pocket of metalloproteinases and the substances which can
show competence to bind with the active site of metallopro-
teinases is much challenging. Considering the species and
technologies explored, it can be said that exploration has just
conﬁned to the tip of an ice berg. With the current cutting
edge scientiﬁc approaches, more marine organisms and their
productscanbeexploredandstudiedforcomingupwiththe
apt marine natural MMPIs.
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